RuminationNCT07478393
Readiness and Progress in Emotion Regulation Therapy
A study testing Emotion Regulation Therapy via Telehealth in people with Rumination and Worry, run by Teachers College, Columbia University at 1 site in United States.
Trial summary
This study is an open trial designed to examine individual changes that occur before, during, and after 6 modules of Emotion Regulation Therapy (ERT) delivered via telehealth for individuals in New York State who are experiencing elevated worry, rumination, or self-criticism. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Rumination, Worry, Self-Criticism
- What is being tested?
- Emotion Regulation Therapy via Telehealth
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Oct 2025to 1 Sep 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Between the ages of 18 and 65
- Fluent in English (and therefore able to provide consent)
- Currently living in New York State
- Access to at least one device with internet and video-conferencing capabilities
- High self-reported worry, rumination, and/or self-criticism
- Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for at least one, current psychological disorder
Who cannot join
- Active suicidal ideation or intent
- Substance dependence disorder, schizophrenia, bipolar-I disorder, or a primary DSM-5 diagnosis of borderline or narcissistic personality disorder
- Currently in therapy or receiving any type of psychosocial treatment
- Individuals taking psychotropic mediation that has not been stabilized for a period of at least 3 months
- Current students at Teachers College, Columbia University
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Teachers College, Columbia University
New York, New York, 10027
Douglas S Mennin, PhD, 212-678-6609, mennin@tc.columbia.edu
About this study
This study is an open trial designed to examine individual changes that occur before, during, and after 6 modules of Emotion Regulation Therapy (ERT) delivered via telehealth for individuals in New York State who are experiencing elevated worry, rumination, or self-criticism.
Read the detailed description
The main questions this study aims to answer are to:
- Examine temporal patterns of ERT-specific treatment mechanisms (attention regulation, metacognitive regulation, motivation regulation, and valued living), relationships between these mechanisms and negative self-referential processing (NSRP; i.e., rumination, worry, and self-criticism) severity over time, and changes in these mechanisms in response to specific intervention strategies/modules.
- Investigate the effect of concordance and/or discordance between therapists and clients regarding skill acquisition, treatment goals, and case conceptualizations on treatment mechanisms as well as measures of treatment outcome and satisfaction.
- Demonstrate the preliminary efficacy of a 6-module, time-variable version of ERT in reducing symptoms of psychological distress (e.g., anxiety, depression, worry, rumination, self-criticism), changing ERT-specific treatment mechanisms (e.g., attention regulation), and improving quality of life and overall functioning.
Participants will:
- Fill out an online pre-screening questionnaire and complete a structured clinical interview via Zoom Healthcare
- Be enrolled as a patient at the Dean Hope Center for Educational and Psychological Services (DHCEPS), located at Teachers College
- Attend between 12-22 once-weekly telehealth ERT sessions
- Complete between 18-28 weekly questionnaires online via Qualtrics (two before starting treatment, 12-22 during each week of treatment, and 4 after ending treatment).
- Conditions
- Rumination, Worry, Self-Criticism, Anxiety, Depression, Distress, Emotional
- Being tested
- Emotion Regulation Therapy via Telehealth
- Keywords
- Worry, Rumination, Self-Criticism, Emotion Regulation Therapy, Emotion Regulation, Treatment Mechanisms
- Medical subject headings
- Rumination Syndrome, Anxiety Disorders, Depression, Emotional Regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Emotion Regulation Therapy via TelehealthBehavioural
Also called Emotion Regulation Therapy (ERT)
The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
| Study group | Role | What they receive |
|---|---|---|
| Emotion Regulation Therapy | Experimental | All participants will receive a 6-module, time-variable version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session. Receives: Behavioral: Emotion Regulation Therapy via Telehealth |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weekly Assessment of Change in Attentional Control
The Attentional Control Scale (ACS) is a 20-item measure used to measure difficulties with concentration associated with problems regulating emotions. Items are rated on a 4-point scale from 1 (almost never) to 4 (always), and raw scores range from 20 to 80. Higher scores indicate better attentional control.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Decentering
The decentering subscale of the Experiences Questionnaire (EQ-D) is an 11-item subscale assessing one's ability to distance themselves from their emotional experience. Items are rated on a 5-point scale from 1 (never) to 5 (all the time), and total scores range from 11 to 55. Higher scores indicate better ability to distancing oneself from one's emotional experience.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Reappraisal
The reappraisal subscale of the Emotion Regulation Questionnaire (ERQ-R) is a 6-item measure of the habitual use of cognitive reappraisal to regulate emotions. Items are rated on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree), and total scores range from 6 to 42. Higher scores indicate a better ability to regulate emotions using the strategy of reappraisal.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Valued Living/Action
The Valuing Questionnaire (VQ) is a 10-item measure of the degree to which respondents have lived according to their personal values over the past week. Items are rated on a 7-point scale from 0 (not at all true) to 6 (completely true). The VQ yields two 5-item subscales: Progress, which assesses enactment of values and perseverance toward them, and Obstruction, which assesses disruption of valued living by avoidance of unwanted experiences and distraction from values. Each subscale ranges from 0 to 30. Higher Progress scores indicate more valued living, and higher Obstruction scores indicate greater interference with valued living.
Measured: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Clarity of Approach-Avoidance Motivation
The Mental Representation of Approach Avoidance Questionnaire (MRAAQ) is a 42-item self-report assessment designed to capture the mental representation of approach-avoidance motivation. Respondents rate how true each statement is for them when they are in an emotional moment, on a 5-point scale from 0 (not at all true for me) to 4 (very true for me). Items are summed into six subscales: Anticipation of Threat (8 items; range 0-32), Consummating Safety (7 items; range 0-28), Anticipation of Reward (8 items; range 0-32), Consummating Reward (7 items; range 0-28), Loss (6 items; range 0-24), and Motivational Clarity (6 items; range 0-24). Higher scores on each subscale indicate greater levels of that motivational process. Higher Anticipation of Threat and Loss scores reflect a worse outcome, whereas higher Consummating Safety, Anticipation of Reward, Consummating Reward, and Motivational Clarity scores reflect a better outcome.
Measured: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Rumination
The Rumination-Reflection Questionnaire (RRQ) is a 12-item measure that assesses past-focused rumination with specificity regarding the types of rumination that people may experience. Items are rated on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree), and total scores range from 12 to 60. Higher scores on this measure indicate greater rumination.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Worry
The Penn State Worry Questionnaire - Past Week (PSWQ-PW) is a 15-item adapted version of the original PSWQ that assesses the extent to which worry has been excessive, uncontrollable, and pervasive in the past week. Items are rated on a 7-point scale from 0 (never) to 6 (almost always), and total scores range from 0 to 90. Higher scores on this measure indicate greater worry in the past week.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Weekly Assessment of Change in Self-Criticism
The self-judgment subscale of the Self-Compassion Scale (SCS) contains 5-items and assesses the tendency to self-criticize. Items are rated on a 5-point scale from 1 (almost never) to 5 (almost always), and total scores range from 5 to 25. Higher scores on this measure indicate greater self-criticism.
Measured: Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks)
Secondary outcomes (2)
Weekly Assessment of Change in Depression Severity
The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank v. 1.0 - Emotional Distress - Depression - Short Form 8a assess for depression severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater depression severity.
Measured: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Weekly Assessment of Change in Anxiety Severity
The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank - Emotional Distress - Anxiety - Short Form 8a assess for anxiety severity. The 8 items are rated on a 5-point scale from 1 (never) to 5 (always), yielding raw scores from 8 to 40. Higher scores on this measure indicate greater anxiety severity.
Measured: Baseline, 1st Treatment Session (2 Weeks Post-Baseline), Follow-Up (4 Weeks Post-Treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start24 Oct 2025
- Primary completion1 Aug 2028 (estimated)
- Study completion1 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RuminationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Teachers College, Columbia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Douglas Mennin, Teachers College, Columbia University
- Investigators
- Douglas S Mennin, Principal investigator, Professor of Clinical Psychology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07478393
- Sponsor's protocol ID
- 25-453
- Status last verified
- Oct 2026
- First submitted
- 12 Mar 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No